About · the editorial binder
About TB-500 Dr
A tabbed binder of the published TB-500 and thymosin beta-4 record — what the studies establish, and what they do not.
What TB-500 Dr is
TB-500 Dr files the peer-reviewed record on TB-500 and its parent protein, thymosin beta-4, into a tabbed binder a reader can work through. The 'Dr' is a reading register, not a practice: no clinic stands behind the binder, no clinician is on staff, and it gives no medical guidance. It makes, sells, distributes, and dispenses nothing.
The site is organized as a tabbed research binder because the TB-500 record is, structurally, a set of sections a careful reader must keep distinct — the synthetic Ac-LKKTETQ heptapeptide versus the full-length protein that carries nearly all the efficacy data, the established mechanism versus the thin human evidence, and the regulatory standing. Each evidence class gets its own divider, and the recurring fragment-versus-full-length caveat runs across the whole binder.
What the "Dr" in the name means
The "Dr" in TB-500 Dr is editorial framing, not a claim about services. It signals the register we work in — a clinical-reference reading of the literature, the kind of tidy evidence folder a careful reader keeps — not the existence of a doctor, a clinic, a pharmacy, or a consultation behind the page. There is no physician here, no clinical team, no prescription service, and no treatment offered. The name describes a position relative to the published record, nothing more.
We make this explicit because the modifier could be misread. It cannot be. Nothing on this site is a diagnosis, a treatment, a prescription, or an offer to supply any substance.
How we handle the evidence
Every quantitative claim on this site is cited to a study collected in the references. We label each finding fragment or full-length thymosin beta-4 so the two are never conflated [6]. We state the safety signals — the tumor and angiogenesis concern, the null and negative preclinical results — alongside the favorable findings [5]. Where the human record is thin, we say it is thin: there are no completed controlled trials of the TB-500 heptapeptide for any indication [6].
We describe doses as administered to a species by a route, never as a human protocol, and we do not present community "loading" schedules as validated [4]. Regulatory facts are stated present-tense and cited to the FDA; we do not assert any future FDA decision as a certainty [19]. If we get something wrong, we want to fix it — see the contact page.